RE:TSO3 south of the borderYou are absolutely correct, IMHO, regarding the medical-legal implications of FDA, and others, changing from 'semi-critical' to 'critical' Spaulding standards for a host of scopes, including duodenscopes, colonoscopes, bronchoscopes, and cystoscopes. I believe this is, in addition to the implications for manufacturer's liabilities and product modifications, why they are being so cautious and slow to implement new recommendations or standards. From discussions that I have had with infection control experts and executives, there appears to be little doubt among the medical professionals that these new sterilization standards are coming, and should come. It is a very difficult job presently for infection control leaders and monitors, especially in hospital operating rooms, with more deadly resistent bacteria being found and more patients exposed or injured. TSO3's solutions are hitting the market at just the right time. For the FDA to change recommendations regarding Spaulding standards, they first needed an effective, reliable, and efficient low temperature sterilzer (complete with reliable biologic indicators and protocols) with impeccible testing and validation. I am sure the FDA is happy to see TSO3's data, as it gives them the opportunity to reset the standard of care in our patients best interests, after all, the latter is the core of their mandate for existing as a regulatory agency. Improving patient care is also, I firmly believe, the primary reason Rumble joined TSO3 in the first place. Wednesday could be a very exciting day.